anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: To obtain a fine particle useful for means for administering a biologically active substance to an egg of birds before hatching without requiring application of a sterilizing means, and capable of suppressing the fear of damaging growing embryo in the egg to minimum. CONSTITUTION: This fine particle is suitable for the use by an injection to an egg having an outer coat and an inner coat and having a liquid between the coats without a part of the egg forming an air chamber with the outer and inner coats, has a size and a density capable of being transferred through the liquid between the both coats to the end of the egg in the opposite side. The fine particle has the density at least same as that of the liquid between the coats, and &lt;=500 μm, preferably 125-250 μm average size. A biologically active material (e.g. a growth hormone releasing factor) is immobilized to the fine particle and injected to the air-tight part of the egg placed so that the air-tight part may be present in the upper part.  A matrix for the fine particle is preferably a polyester selected from polylactide polymer, polyglycoside polymer and lactic acid-glycolic acid copolymer.
PROBLEM TO BE SOLVED: To obtain the subject particle having an enlarged specific surface area, capable of exhibiting a high effect as a microorganism flocculating agent by bonding an organic group containing a pyridinium base to a fine inorganic particle. SOLUTION: This inorganic particle comprises an organic group containing pyridinium base on the surface. The inorganic particle is preferably selected from a metal, a metal oxide, a metal nitride, a metal carbide and a metal sulfide and the diameter of the inorganic particle is preferably &lt;=5 μm, preferably &lt;=1 μm. The organic group is preferably a polymer. The bonding of the organic group containing the pyridinium base to the inorganic particle can be carried out by formulating an organic group precursor containing the pyridinium base with the inorganic particle in a proper solvent or by a reaction such as hydrolysis or condensation. Preferably, a substance having selective bondability (preferably an antigen or an antibody) is bonded to the surface of the inorganic particle.
PURPOSE:To titled composition, obtained by blending a physiologically active substance sparingly soluble in water as an active ingredient with an inorganic Ca salt and alginate, nondisintegrable in animal oral cavity and rumen, capable of exhibiting disintegrating property in and after the abomasum and having improved palatability. CONSTITUTION:A medicinal composition obtained by granulating a physiologically active substance sparingly soluble in water with an inorganic calcium salt, e.g. calcium carbonate, calcium primary phosphate, etc. as an excipient and an alginate, e.g. sodium alginate, etc., as a binder. The contents of the ingredients in the composition are preferably 20-40% inorganic calcium salt and &gt;=0.01% alginte.
&lt;P&gt;PROBLEM TO BE SOLVED: To treat various disorders or diseases related to activity of JAK, JNK, CDK and ZAP-70.  &lt;P&gt;SOLUTION: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof, pharmaceutically acceptable compositions containing the compounds and a method of treating various protein kinase-mediated disorders by using those compounds and compositions. The followings are discovered: the compounds and the pharmaceutically acceptable compositions thereof are effective as JAK, JNK, CDK and ZAP-70 protein kinase inhibitors. In certain embodiments, the compounds are effective as JAK, JNK. CDK and ZAP-70 protein kinase inhibitors.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To stabilize posttransplant adhesion of hematopoietic stem cells, adhesion after transplantation, by using an HLA-concordant activated lymphocyte.  &lt;P&gt;SOLUTION: A posttransplant adhesion stabilizing composition of the hematopoietic stem cell is prepared by proliferating or activating the HLA-concordant lymphocyte in a mononuclear cell separated from peripheral blood or cord blood, then separating and collecting the lymphocyte, so that the composition containing the HLA-concordant activated lymphocyte as the main ingredient is obtained. Thus, the composition is widely used for preventing insufficiency of the posttransplant adhesion of hematopoietic stem cells, accelerating and treating the the adhesion, etc. Further, an amount of the composition to be administered is varied according to an age of a patient, a disease condition thereof, etc., but it is preferable that the composition is administered to a mammal, including a human, in an amount of 0.2-20 mg/kg/day as a hominization antibody. The composition is administered by an intravenous injection once a day (single administration or every-day administration), intermittently one to three times a week, or once per two or three weeks.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
NEW MATERIAL:An interferon-beta-production promoter having 550000-650000 molecular weight, 1.5(mug/ml) sugar content, 4.0(mug/ml) protein content, 0.4 ratio of (sugar/protein) and 168 (IU/mug sugar) specific activity. USE:A food component having a high safety and a biophylaxis effect. PREPARATION:For example, cow&#39;s milk is fermented using Yeast kefir (Russian type YK-1) and the resultant product is freeze dried to prepare p-dery kefir. The resultant powdery kefir is extracted using 10mM sodium phosphate buffer solution (pH7.0) and the extracted solution is subjected to gel filtration to collect an active fraction. The obtained active fraction is then subjected to ion-exchange chromatography using a weak anion-exchange column resin and the adsorbates are eluted using 50mM NaCl. The eluted fraction is concentrated and then subjected to gel filtration, thus obtaining the objective interferon-beta production promoter having 550000-650000 molecular weight.
&lt;P&gt;PROBLEM TO BE SOLVED: To realize Alpinia speciosa vinegar capable of more effectively exhibiting the effect and utilize coal of Alpinia speciosa left after dry distillation or bagasse coal after squeezing sugarcane as a soil-improving agent in regard to vinegar of Alpinia speciosa collected from smoke by dry-distilling Alipinia speciosa and a method for utilizing the Alipinia speciosa vinegar.  &lt;P&gt;SOLUTION: The stem of Alpinia speciosa in which at least outer skin part is dried is put in a dry distillation oven and dry-distilled and the Alpinia speciosa vinegar is collected from smoke generated in this time. Coal left after dry distillation is used as the soil-improving material, etc. The Alpinia speciosa vinegar collected from smoke is formulated with pyroligneous acid or bamboo vinegar to provide an Alpinia speciosa vinegar product. The Alpinia speciosa vinegar or the other liquid is impregnated into Alpinia speciosa coal or sugarcane bagasse coal obtained by dry-distilling the stem of Alpinia speciosa or sugarcane bagasse and the impregnated material is used as the soil-improving material or a material for insect proof.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To provide the highly safe composition containing a benzylidene phthalide derivative and a coumarin derivative contained in the extract of Hydrangeae macrophylla Seringe var. thunbergii Sugimoto, a natural material, and having excellent foul breath-preventing and periodontosis-preventing effects. CONSTITUTION:This composition for oral cavity contains a coumarin derivative of formula I (A is H, OH; X, Y are H, hydroxy, methoxy; Q is six-membered lactone ring) (e.g. phyllodulcin of formula II, hydrangenol of formula III) and a benzylidene phthalide derivative (e.g. 7,3&#39;,4&#39;-trihydroxybenzylidene phthalide of formula IV). The counmarin derivative of formula I is obtained from the extract of Hydrangeae macrophylla Seringe var. thunbergii Sugimoto in the form of a single substance or a mixture. These ingredients are preferably compounded in amounts of 0.001-20wt.%, especially 0.005-5wt.% respectively.
PROBLEM TO BE SOLVED: To obtain tablets having good color dispersion and development without causing them to be broken by tabletting pressure by dispersing carotenoid pigment crystals in a state not dissolved in fat and oil in a water-soluble material comprising an emulsifier, an excipient and an antioxidant, pulverizing the crystals with a grinder to form a dry powder and using this powder. SOLUTION: Although not particularly limited, the carotenoid pigment is selected among β-carotene, canthaxanthin, β-apo-8&#39;-carotenal, leupin, lutein, etc. The emulsifier is exemplified by a food material having emulsion stabilizing effect such as a sucrose fatty acid ester, lecitin, a glycerol fatty acid ester, soybean saponin, arabic gum, pectin, dextrin or casein. The excipient used is a food processing material such as dextrin or starch. The antioxidant used is ascorbic acid or cetechin having antioxidant effect on fat and oil. The comminuted carotenoid pigment crystals have a particle diameter of 2μm or below, desirably 0.5μm or below.
The present invention relates to a smartphone-based personal medical information collecting system. The smartphone-based personal medical information collecting system comprises: a medical institution server which encrypts and provides medical information; a National Health Insurance Service server which encrypts and provides personal medical information; another healthcare platform servers which encrypts and provides personal healthcare information; a personal medical device which encrypts and provides biometrics; a personal terminal which includes a smartphone, a smart pad, and a personal portable terminal, wherein the personal terminal includes a collection application collecting health information and other information; and a PHR platform server which is connected to the personal terminal through communication to transmit a healthcare record including a personal medical record, a biorhythm, and an exercise record. To protect the personal information, the personal medical record is collected using a user&#39;s smartphone and stored in a personal health record (PHR) platform. Information to be collected includes medical records from a medical institution, health examination records from the National Health Insurance Service, life logs from the other healthcare platform (Google, Apple, Samsung), and records measured by the personal medical device. Log-in information to be collected of a the system is encrypted and stored in a personal smartphone. The collection application stores only a personal medical record collected into the PHR platform. The personal medical record stored in the PHR platform is used for various healthcare services.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to gynecology and can be used for treatment of benign lesions of cervix, including those complicated by nabothian cysts. For this purpose prepared is special suspension, consisting of one part of sterile powder of medical polymer-salt nanosized composite implantation collagen-containing material and two parts of two-percent lidocaine solution. After that, all affected in process of disease cervix surface is infiltrated with said special suspension until 0.5-1 mm thick continuous infiltration cushion is formed under affected by disease surface. In preferable version of invention, as medical polymer-salt nanosized composite implantation collagen-containing material, used is medical material &#34;LitAr&#34;. ^ EFFECT: method makes it possible to simplify and make cheaper treatment of benign cervix lesions. ^ 6 cl, 2 ex
PURPOSE:To obtain a drug having improved bioavailability, by esterifying the carboxyl of a drug having a carboxyl group with a novel 1,3-dioxolen-2-one derivative, a modifying agent for a prodrug of a drug. CONSTITUTION:A drug such as ampicillin, etc. having a carboxyl group is reacted with a 1,3-dioxolen-2-one derivative (e.g., 4-bromomethyl-5-methyl-1,3-dioxolen-3-one, etc.) shown by the formulaI(R&lt;1&gt; is H, lower alkyl, or aryl; R&lt;2&gt; is H or R&lt;1&gt; and R&lt;2&gt; may be linked to form a ring; X is halogen), so that the caboxyl is esterified to give a drug having improved bioavailability. The novel compound shown by the formulaI, for example, is prepared by reacting a compound shown by the formula II with a halogenating agent under conditions to produce a radical. EFFECT:Esterification of the drug makes it stable in gastric juice and intestinal juice. When it is absorbed in the intestine, it is hydrolyzed by the action of an enzyme in the body, restored to the original compound, and shows medicinal effects.
FIELD: microbiology, biotechnology. SUBSTANCE: vaccine is introduced, in equal portions by volume, with dead pasteurella of standardized fist-generation microbial cell both in capsular and capsule-free variants after isolation out of poultry body. For this purpose, a susceptible organism should be infected orally with a control-industrial pasteurella strain obtained by the method of pasteurella virulence increase, and at the moment of lethality one should wash maternal capsule- free bacteria in heated buffered physiological solution of sodium chloride (pH 7.0; 35-40 C), immediately after cooling off and postmortem rigidity at environmental temperature being 15-25 C (optimum 20 C) (in 3-4 h after death depending upon body weight of affected poultry) - maternal capsular bacteria which are separately inoculated, correspondingly, upon Hottinger&#39;s broth heated up to 37-38 C (pH 7.2-7.4) to be cultivated upon nutritive medium identical both by quality and temperature. At 9-10-h age of every pasteurella culture one should pour off, correspondingly, per a half of their volume into sterile vials and cool gradually for 2-3 h at environmental temperature being 15-25 C (optimum 20 C) till complete encapsulation of microbial cells at the state of rest. Then it is necessary to simultaneously introduce formalin at final concentration being 0.3% into cooled halves of encapsulated cultures and continuously cultivated halves of capsule-free pasteurella cultures. Concentrated biomass of capsular and capsule-free pasteurella, correspondingly, should be combined at equal portions by volume to prepare working suspension of vaccine antigen in buffered physiological solution of sodium chloride at 0.3%-formalin concentration at 30 bln mc/ml. Working antigenic suspension should be mixed with known oily adjuvant at equal ratio by volume to be used as the vaccine. The latter is safe being immunogenic and economically harmless. EFFECT: higher efficiency of prophylaxis. 2 cl, 7 ex, 4 tbl
PROBLEM TO BE SOLVED: To obtain a hair-decoloring agent little in the damage to hair, giving strong and uniform decoloration effects, and good in the finished appearance. SOLUTION: This hair-decoloring agent contains 1-50wt.% of a persulfate salt (e.g. sodium persulfate), 0.1-20wt.% of an oxidizing agent (e.g. hydrogen peroxide), and 0.01-10wt.% of a higher alcohol (e.g. stearyl alcohol) as active ingredients. It is essential that the total amount of a lower alcohol (e.g. ethanol) and a polyhydric alcohol (e.g. polyethylene glycol) is &lt;=10% on the employment of the hair-decoloring agent. The addition of the higher alcohol accelerates the spreading and impregnation of the agent liquid into the hair. The control of the hole amount of the lower alcohol and the polyhydric alcohol to &lt;=10% enables to uniformly and strongly decolor the hairs ranging from the high temperature root parts to the relatively low temperature hair tip parts, and further improves the finishing appearance.  The addition of a cationic surfactant or a cationized polymer extremely improves the hair-protecting action and the finishing appearance.
The application discloses a accompanying method, a device and terminal equipment. The method and the device can be applied to terminal equipment corresponding to the accompanying person, such as an intelligent bracelet, an intelligent electronic ornament and the like. Firstly, the data of the accompanying person needs to be collected, wherein the data comprises one of the following data: sound data, expression data, motion data and physical sign data; then, analyzing the data of the person to be accompanied to determine a corresponding accompanying mode; the accompanying mode includes at least one of: a voice response mode, a psychological consultation mode and an emergency mode; and finally accompanying the person to be accompanied according to the accompanying mode. This application can match the mode that suits and accompany according to the actual conditions by the attendant. Accompanying mode is abundant various, consequently can richen by accompanying person&#39;s experience of being accompanied by, promotes the effect of accompanying and attending to. In addition, this application technical scheme can realize on the terminal equipment of various forms, does not confine to intelligent robot, therefore greatly reduced accompany and attend to the spending, convenient and practical.
1,146,991. Steroids. UPJOHN CO. 6 April, 1966 [7 April, 1965], No. 15372/66. Heading C2U. Novel compounds of the formula wherein Z and Z&lt;SP&gt;1&lt;/SP&gt; represent hydrogen, the lower acyl radical of a hydrocarbon carboxylic acid containing from one to twelve carbon atoms, inclusive, or di- or tetrahydropyranyl, Q represents C#CA, R 1 , R 4  and CH 2 CH 2 A wherein A represents hydrogen, lower alkyl of from one to twelve carbon atoms, inclusive, chlorine, bromine, or trifluoromethyl, R 1  and R 2  represent hydrogen or methyl and R 4  is lower alkyl of from one to twelve carbon atoms, inclusive, are prepared by treating in the presence of cuprous chloride catalyst with a methyl magnesium halide, a corresponding compound of the formula wherein R 1 , R 2  and Q have the same meaning as above, followed by the treatment with an anhydride of an organic carboxylic acid containing one to twelve carbon atoms inclusive, to yield the corresponding compound of the formula wherein Ac is the acyl radical of an organic carboxylic acid containing from one to twelve carbon atoms, inclusive, R 1 , R 2  and Q have the same meanings as above; and treating the thus produced compound with sodium borohydride. The 17α-alkynyl compounds may be reduced with hydrogen in the presence of a palladium catalyst to the corresponding saturated compounds. The 3#,17#- 5- androstene 3-dihydropyranyl ethers are obtained by benzoylating a 17#-4-androsten-3-one to obtain a 17-benzoate, enol acylating the latter and reducing with sodium borohydride to obtain a 3#,17# - dihydroxy - 4 - androsten 17 - benzoate, etherifying the latter with dihydropyran and hydrolysing off the 17-benzoate grouping. Conversion of the products to 3-monoacylates and 3,17-diacylates may be effected with an anhydride or acyl chloride of an organic carboxylic acid. Pharmaceutical compositions having anabolic, androgenic, gonadotropin inhibiting, anti-fertility, anti-androgenic and anti-estrogenic activities and containing the above compounds are administered orally or parenterally.
Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein. ® KIPO &amp; WIPO 2009
Methods for preconditioning, treating and/or providing neuroprotection to the animal central nervous system against the effects of neurodegeneration caused by iron accumulation in the brain. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. An examplary therapeutic agent is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for or diagnosed with neurodegeneration caused by iron accumulation in the brain. The effective amount of DFO is delivered directly to the patient&#39;s central nervous system for preconditioning, preventing and/or treating neurodegeneration caused by iron accumulation in the brain.
NEW MATERIAL:A compound expressed by formula I (R&lt;1&gt; is lower alkyl, lower alkoxyl, halogen, etc.; R&lt;2&gt; is H or lower alkyl which may have a substituent group; n is 0, 1 or 2; m is 1 or 2) and a salt thereof. EXAMPLE:2-[4-( 1-Methyl-cis-4-tert-butylcyclohexyloxy )anilino]-3-( 4-methoxyphenyl)propionic acid. USE:Having the increasing action on high-density lipoprotein (HDL) cholesterol, and useful for treatment and prevention of arteriosclerosis. PREPARATION:A compound expressed by formula II is reacted with a compound expressed by formula III in the presence of a strong base, e.g. metallic sodium, to give a compound expressed by formula IV, and the nitro group of the resultant compound expressed by formula IV is reduced to form a compound expressed by formula V. The resultant compound expressed by formula V is then reacted with an alpha-halogeno-alpha-substituted acetic acid derivative expressed by formula VI in the presence of a deacidifying agent, e.g. pyridine, to afford the aimed compound expressed by formula I .
Systems, methods, and computer program products are provided that can facilitate providing secure, on-line communications between healthcare providers and remotely located patients. Patients, during on-line virtual office visits, provide various information about one or more medical conditions in a predetermined, structured format. Patients are assigned to pools of patients based upon one or more patient attributes and/or one or more healthcare provider attributes. A healthcare provider qualified to treat patients in the pool selects a patient from a displayed list and views the medical condition of the patient. The physician prepares a diagnosis and/or treatment recommendation for the medical condition(s) of the patient and sends a communication containing the same to a secure area. The patient is then notified of the physician&#39;s communication and is directed to log-on to the secure area and view the communication.
PURPOSE:To obtain as a synthetic intermediate for macrolides useful as antiulcer agents, antimicrobial agents, etc. CONSTITUTION:A compound expressed by formula I (R&lt;1&gt; is tert. butyldiphenylsilyl, tert. butyldimethylsilyl, methoxymethyl, acetyl or benzoyl). The compound is obtained by reacting a compound expressed by formula II (Me is methyl) with tert. BuPh2SiCl and imidazole used as reagents in a solvent of DMF at 0 deg.C to ambient temperature for 1-5hr. Lactol expressed by formula II is obtained by reacting a lactone expressed by formula III with a diisobutylalminamhydride reagent in a solvent such as toluene. By using this intermediate, macrolides can be stereoselectively produced in high yield and purity.